Treats Parkinson's disease, post-encephalitic parkinsonism, and symptomatic parkinsonism. ANDA 78536, held by Sun Pharm Inds. Carbidopa; Levodopa.
As of Nov 16, 2026, ANDA 78536 (Carbidopa And Levodopa), held by Sun Pharm Inds, was first approved by FDA on Oct 28, 2008, with 6 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE Carbidopa and levodopa tablets, USP are indicated in the treatment of Parkinson's disease, post-encephalitic parkinsonism, and symptomatic parkinsonism that may follow carbon monoxide intoxication or manganese intoxication. Carbidopa allows patients treated for Parkinson's disease to use much lower doses of levodopa. Some patients who responded poorly to levodopa have improved on carbidopa and levodopa tablets, USP. This is most likely due to decreased peripheral decarboxylation of levodopa caused by administration of carbidopa rather than by a primary effect of carbidopa on the nervous system. Carbidopa has not been shown to enhance the intrinsic efficacy of levodopa.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Oct 28, 2008 | Original application | Approved | None posted |
| Carbidopa And Levodopa10MG;100MG · tablet;oral | Carbidopa; Levodopa | Rx |
| Carbidopa And Levodopa25MG;100MG · tablet;oral | Carbidopa; Levodopa | Rx |
| Carbidopa And Levodopa25MG;250MG · tablet;oral | Carbidopa; Levodopa | Rx |
| Sep 11, 2026 | Supplement 28Labeling · Standard review | Approved | None posted |
| Feb 9, 2021 | Supplement 23Labeling · Standard review | Approved | None posted |
| Jul 10, 2018 | Supplement 15Manufacturing | Approved | None posted |
| Feb 6, 2015 | Supplement 12Labeling · Standard review | Approved | None posted |
| Apr 5, 2013 | Supplement 8Labeling · Standard review | Approved | None posted |
| Oct 4, 2010 | Supplement 3Labeling | Approved | None posted |
| Oct 28, 2008 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters